FDA Approves Retevmo for Certain Lung, Thyroid Cancers

MONDAY, May 11, 2020 — Retevmo (selpercatinib) capsules have been approved to treat patients with non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other thyroid cancers with an alteration in the “rearranged during…
Source: Topamax